|
| Study group and year | Number of patients | Tumor data | Tumor size* (mm) | Indications | Freeze/thaw cycle | Follow-up | LCR | Survival |
|
| Wang et al. [17], 2005 | 187: 165 NSCLC (5 stage I, 17 stage II, 80 stage III, and 63 stage IV), 22 metastasis | 234 tumors: 196 primary cancer and 38 metastasis | in peripheral locations and in central locations | Local control and palliation | Double | NA | NA | NA |
|
| Kawamura et al. [18], 2006 | 20: all metastasis | 35 | Mean tumor size, 13.3 | Local control | Triple | 9 to 28 months (median, 21 months) | LCR: 80% | 1 y OS: 89.4% |
|
| Zemlyak et al. [35], 2010 | 27: all NSCLC (27 stage I) | 27 | NA | Local control | NA | Mean, 33 months | LCR: 89% | 3 y OS/cancer-specific survival/cancer-free survival rate: 77.0%/90.2%/45.6%, respectively |
|
| Yamauchi et al. [28], 2011 | 24: all metastasis | 55 | | Local control | Triple | Median, 40 months | 1 /3 y LCR: 90.8% and 59%, respectively, 3 y LCR of tumors <15 mm and >15 mm: 79.8% and 28.6%, respectively () | 1 /3 y OS: 91%/59.6%, respectively |
|
| Zhang et al. [14], 2012 | 46: all NSCLC (12 stage I, 19 stage II, and 15 stage III) | 46 | | Local control | Double | 24 months | 2 y LCR: 83.7%. | 2 y OS: 93.5%. |
|
| Pusceddu et al. [19], 2013 | 32: 11 NSCLC (4 stage I, 3 stage II, 3 stage III, and 1 stage IV), 21 metastasis | 34 tumors: 11 primary cancer and 23 metastasis | | Local control | Double or triple | 6 months | 1 /3 /6 mo technical success: 82%/97%/91%, respectively | NA |
|
| Yamauchi et al. [8], 2012 | 22: all NSCLC (22 stage I) | 34 | | Local control | Triple | 12 to 68 months (median, 23 months) | LCR of 97% | 2 /3 y OS: 88%/88%, respectively |
|
| Yashiro et al. [27], 2013 | 71 (patients characteristics were not reported) | 210 tumors: 11 primary cancer and 199 metastasis | Mean tumor size, 12.8 | Local control | Triple | 79 to 2467 days (median, 454 days) | 1 /2 /3 y LCR: 80.4%/69.0%/67.7%, respectively | NA |
|
